ABL Europe’s GMP manufacturing facility for viral vector production
ABL Europe’s GMP manufacturing facility for viral vector production
6 PagesABL Europe’s GMP manufacturing facility for viral vector production New Production Capacity for Viral Vectors ABL Europe GMP manufacturing of viral vectors from non-adherent cell cultures Success Story January 2018 – A new production facility for the GMP manufacture of viral vectors from non-adherent cell cultures is opening in Strasbourg, France. This will alleviate growing concerns that a lack of suitable manufacturing capacity is restricting the speed with which this nascent industry is able to bring viral vector products from the laboratory to the patient. He believes CEOs of companies developing viral vectors are coming under increasing pressure to bring their products to market since Amgen’s successful registration of the T-VEC oncolytic viral vector product showed t
